Objectives To assess the effects and safety of Astragalus membranaceus injection on clinical and indirect outcomes in patients with viral myocarditis.
Methods Randomised controlled trials of Astragalus membranaceus injection (with a minimum of seven days treatment duration) compared with placebo, no intervention, or conventional interventions were included.
Results Nine randomised controlled trials involving 894 people were included. All trials were conducted and published in China. None of the trials reported outcomes on mortality and quality of life. The trials reported electrocardiogram results, level of myocardial enzymes, cardiac function, and adverse effects.
Conclusions The present systematic review suggests that Astragalus membranaceus injection has positive effects in patients with suspected viral myocarditis in abnormal electrocardiogram and improving myocardial enzymes. No significant effects were found on mortality and the incidence of complications.